Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
FDA Approves Dupixent Injections For People Struggling With COPD Symptoms
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
Monthly Prescribing Reference15h
Dupixent Approved as Add-On Maintenance Therapy in COPD
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
copdnewstoday16h
FDA approves Dupixent for adults with poorly controlled COPD
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
Buy Rating on Apogee Therapeutics’ APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape
Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...